Intra-Cellular Therapies (ITCI) PT Raised to $74 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Join SI Premium – FREE
Mizuho Securities analyst Graig Suvannavejh raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $74.00 (from $66.00) while maintaining a Buy rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Sandfire Resources NL (SFR:AU) (SNDFY) PT Lowered to AUD25 at Canaccord
- Stella-Jones Inc. (SJ:CN) (STLJF) PT Lowered to Cdn$76 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
